J. Safra Sarasin Holding AG Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

J. Safra Sarasin Holding AG cut its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 80,972 shares of the company's stock after selling 12,497 shares during the period. Eli Lilly and Company makes up 1.1% of J. Safra Sarasin Holding AG's holdings, making the stock its 29th largest position. J. Safra Sarasin Holding AG's holdings in Eli Lilly and Company were worth $62,510,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of LLY. Highline Wealth Partners LLC raised its position in Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after buying an additional 20 shares during the last quarter. FPC Investment Advisory Inc. lifted its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $58,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley dropped their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,017.00.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $31.69 on Thursday, hitting $861.11. 2,936,578 shares of the company were exchanged, compared to its average volume of 3,430,652. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a 50-day moving average price of $826.81 and a 200 day moving average price of $819.07. The stock has a market capitalization of $816.48 billion, a price-to-earnings ratio of 73.54, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.